Zhenlin Huang

Key Laboratory Of Urinary Tumors
Zhengzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Docetaxel induced activation of GSDME pathway and pyroptosis enhance immune lethality in prostate cancer cells.

Docetaxel induced activation of GSDME pathway and pyroptosis enhance immune lethality in prostate cancer cells.

Journal: Journal of experimental & clinical cancer research : CR

Published: August 21, 2025

Targeted inhibition of the CREB1-CtIP axis enhances the efficacy of abiraterone combined with radiotherapy in prostate cancer.

Targeted inhibition of the CREB1-CtIP axis enhances the efficacy of abiraterone combined with radiotherapy in prostate cancer.

Journal: Cell death & disease

Published: July 14, 2025

DNA2 protein destruction dictates DNA hyperexcision, cGAS-STING activation, and innate immune response in CDK12-deregulated cancers.

DNA2 protein destruction dictates DNA hyperexcision, cGAS-STING activation, and innate immune response in CDK12-deregulated cancers.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: July 07, 2025

The Oncopromoting Gene RBM6 Inhibits Prostate Tumour Cell Migration During Epithelial-to-Mesenchymal Transition.

The Oncopromoting Gene RBM6 Inhibits Prostate Tumour Cell Migration During Epithelial-to-Mesenchymal Transition.

Journal: Journal of cellular and molecular medicine

Published: November 29, 2024

Vitamin A and its influence on tumour extracellular matrix.

Vitamin A and its influence on tumour extracellular matrix.

Journal: Discover oncology

Published: October 02, 2024

Phosphatase LHPP confers prostate cancer ferroptosis activation by modulating the AKT-SKP2-ACSL4 pathway.

Phosphatase LHPP confers prostate cancer ferroptosis activation by modulating the AKT-SKP2-ACSL4 pathway.

Journal: Cell death & disease

Published: April 16, 2024

Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators.

Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators.

Journal: Cell death & disease

Published: March 01, 2024

SYT4 binds to SNAP25 to facilitate exosomal secretion and prostate cancer enzalutamide resistance.

SYT4 binds to SNAP25 to facilitate exosomal secretion and prostate cancer enzalutamide resistance.

Journal: Cancer science

Published: January 12, 2024

LINC00645 inhibits renal cell carcinoma progression by interacting with HNRNPA2B1 to regulate the ROCK1 mRNA stability.

LINC00645 inhibits renal cell carcinoma progression by interacting with HNRNPA2B1 to regulate the ROCK1 mRNA stability.

Journal: Gene

Published: November 16, 2023

8-Br-cGMP activates HSPB6 and increases the antineoplastic activity of quinidine in prostate cancer.

8-Br-cGMP activates HSPB6 and increases the antineoplastic activity of quinidine in prostate cancer.

Journal: Cell death discovery

Published: September 23, 2023

TrkA promotes MDM2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression.

TrkA promotes MDM2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression.

Journal: Journal of experimental & clinical cancer research : CR

Published: September 14, 2023

Transcriptomic insights into UTUC: role of inflammatory fibrosis and potential for personalized treatment.

Transcriptomic insights into UTUC: role of inflammatory fibrosis and potential for personalized treatment.

Journal: Journal of translational medicine

Published: September 14, 2023

Showing 1-12 of 25

Last Updated: 09/26/2026